Skip to content

A novel HER2-positive breast cancer phenotype arising from germline TP53 mutations

Research output: Contribution to journalArticlepeer-review

  • J. R. F. Wilson
  • A. C. Bateman
  • H. Hanson
  • Dr Qian An
  • G. Evans
  • N. Rahman
  • J. L. Jones
  • D. Eccles
The Li–Fraumeni Syndrome is caused by a germline TP53 mutation and is associated with a high risk of breast cancer at young ages. Basal (triple negative) breast cancers are now well recognised to be a typical sub-type of breast cancer developing in a large proportion of BRCA1 gene carriers. We considered whether a similar narrow sub-type of breast cancer was found in TP53 gene mutation carriers. Objective: A hypothesis generating study to investigate whether there are specific breast tumour characteristics associated with germline TP53 mutations. Methods: Pathological characteristics in 12 breast cancers arising in nine patients carrying pathogenic TP53 mutations were compared to a reference panel of 231 young onset breast tumours included in the POSH study. Results: Patients carrying a TP53 mutation showed a significantly higher likelihood of developing a breast cancer with Human Epidermal growth factor Receptor (HER2) amplification (83%) when compared to the cohort of young onset breast cancer cases (16%); ER and PR status were equivalent between groups. Conclusion: These findings suggest that breast cancer developing on a background of an inherited TP53 mutation is highly likely to present with amplification of HER2.
Original languageEnglish
Pages (from-to)771-774
JournalJournal of Medical Genetics
Publication statusPublished - 2010

Related information

Relations Get citation (various referencing formats)

ID: 93215